Mixed News on Avastin

From the 33rd Annual San Antonio Breast Cancer Symposium:

Avastin (Bevacizumab) may be successful in fighting triple-negative, but shows no benefit for early breast cancer in other patients. The FDA is expected to announce later this month whether it will continue to approve use of the drug. Read the full story on Medscape Today.